NGD 98-2 hydrochloride
High affinity antagonist of corticotropin-releasing factor receptor 1 (CRF1) (Ki = 1 nM). Orally available and brain penetrant.
|Storage||Desiccate at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
|water||2.18||5mM with gentle warming|
Preparing Stock Solutions
The following data is based on the product molecular weight 435.87. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.29 mL||11.47 mL||22.94 mL|
|5 mM||0.46 mL||2.29 mL||4.59 mL|
|10 mM||0.23 mL||1.15 mL||2.29 mL|
|50 mM||0.05 mL||0.23 mL||0.46 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Hodgetts et al (2011) Discovery of N-(1-ethylpropyl)-[3-methoxy-5-(2-methoxy-4-trifluoromethoxyphenyl)-6-methyl-pyrazin-2-yl]amine 59 (NGD 98-2): an orally active corticotropin releasing factor-1 (CRF-1) receptor antagonist. J.Med.Chem. 54 4187 PMID: 21618986
If you know of a relevant reference for NGD 98-2 hydrochloride, please let us know.
View Related Products by Product Action
Keywords: NGD982 corticotrophin corticotropin-release releasing factor receptors antagonists CFR-1 CRF1 high affinity CRF1 Receptors
Citations for NGD 98-2 hydrochloride
Citations are publications that use Tocris products.
Currently there are no citations for NGD 98-2 hydrochloride. Do you know of a great paper that uses NGD 98-2 hydrochloride from Tocris? If so please let us know.
Literature in this Area
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.